Faulty Protein Condensates Drive Congenital Heart Defects via Notch Shutdown
A newly identified molecular glitch in MAML1 phase separation disrupts Notch signaling and causes ventricular septal defects.
Summary
Researchers discovered that a protein called MAML1, which normally forms liquid-like droplets in the cell nucleus to activate heart-development signals, can malfunction in people born with congenital heart disease. When MAML1 carries certain genetic mutations, these droplets fail to form properly, shutting down a critical signaling pathway called Notch that guides early heart development. Using patient DNA, genetically engineered mice, and lab-grown human heart organoids, the team showed that disrupted MAML1 droplet formation prevents proper formation of the heart's walls and valves. They also found that a specific enzyme, PKN2, can further destabilize these droplets through chemical modification, revealing a two-hit regulatory axis that may underlie multiple forms of congenital heart malformation.
Detailed Summary
Congenital heart disease (CHD) is the most common structural birth defect worldwide, affecting roughly 1 in 100 newborns and remaining a leading cause of infant death. Dysregulated Notch signaling is a well-known driver, but the precise molecular mechanisms have been incomplete. This study fills a critical gap by identifying MAML1 — a transcriptional coactivator of the Notch pathway — as a CHD candidate gene and revealing that its ability to form liquid-liquid phase separation (LLPS) condensates in the nucleus is essential for normal heart development.
The researchers screened a clinical cohort of CHD patients and identified rare MAML1 missense variants, including the Q401K mutation, enriched in individuals with ventricular septal defects. They then modeled this variant in knock-in mice, endocardium-specific Maml1 knockout mice, and CRISPR-edited human heart organoids — three complementary systems that together recapitulated the septal and valvular defects seen in patients.
Mechanistically, MAML1 normally forms nuclear condensates via LLPS in the intrinsically disordered region 2 (IDR2), and these condensates are required for efficient physical interaction with the NOTCH1 intracellular domain and activation of downstream Notch target genes. Pathogenic charge-altering mutations like Q401K abolish IDR2's electrostatic properties, preventing condensate formation and thereby silencing Notch transcription. Separately, the kinase PKN2 phosphorylates MAML1 at Serine 314, destabilizing condensates and attenuating Notch output — suggesting that both genetic and post-translational mechanisms converge on the same biophysical vulnerability.
These findings reframe CHD pathogenesis around biophysical condensate biology and open potential avenues for genetic counseling and therapeutic targeting of the PKN2-MAML1-Notch axis.
Caveats include reliance on the abstract alone, and the translational distance between mouse/organoid models and human therapeutic intervention remains substantial.
Key Findings
- Rare MAML1 missense variants, including Q401K, are associated with ventricular septal defects in CHD patients.
- MAML1 must form liquid-liquid phase separation condensates to activate Notch signaling during heart development.
- Charge-altering mutations in MAML1's disordered region 2 abolish condensate formation and suppress Notch transcription.
- PKN2 kinase phosphorylates MAML1 at Ser314, destabilizing condensates and further dampening Notch output.
- Endocardium-specific MAML1 loss disrupts endocardial-to-mesenchymal transition, causing septal and valvular defects.
Methodology
The study combined a clinical CHD patient cohort with three experimental models: Q401K knock-in mice, endocardium-specific Maml1 knockout mice, and CRISPR-edited human heart organoids. Cardiac phenotypes were assessed by echocardiography and histology, while LLPS dynamics were characterized by microscopy and biochemical assays, and the upstream regulatory kinase was identified via mass spectrometry.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so methodological details and statistical analyses could not be fully evaluated. The experimental models are primarily murine and organoid-based, and translation to human therapeutic strategies requires further validation. The clinical cohort size for MAML1 variant discovery is not specified in the abstract, limiting assessment of statistical power.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.